Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Philip Frndak

Orthopaedic Surgery Meadville, PA Doctor of Osteopathy

NPI 1144290511 CMS profile 97492

321 Arch Street Ste 101, Meadville, PA 16335

Open in the dashboard

General payments

$53,174

41 records reported · program years 2019–2024

Research payments

$84,128

Paid to them · 12 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Philip Frndak of Meadville, PA is reported in the CMS Open Payments database as having received $53,174 across 41 general payments and $84,128 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $5,800 2
2023 General $500 1
2022 General $24,481 7
2021 General $17,817 8
2021 Research $27,643 3
2020 General $3,311 10
2020 Research $43,355 7
2019 General $1,265 13
2019 Research $13,130 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Frndak
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Philip Frndak were reported at $0. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Philip Frndak Orthopaedic Surgery median Middle half National median
2019 $1,265 $644 $140–$2,844 $163
2020 $3,311 $312 $75–$1,860 $114
2021 $17,817 $520 $117–$2,495 $132
2022 $24,481 $598 $128–$2,731 $149
2023 $500 $461 $128–$2,264 $160
2024 $5,800 $497 $134–$2,475 $164
2025 $0 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medacta USA, Inc. $53,174 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $50,000 11 payments
  2. Travel and Lodging $2,209 16 payments
  3. Food and Beverage $965 14 payments
Products named General payments · program years 2019–2024
  1. GMK SPHERE $21,215 17 payments
  2. GMK Sphere Revision System $5,800 2 payments
  3. AMISTEM $2,179 16 payments
  4. EFFICIENCY $104 1 payment
  5. MASTERLOC $70 3 payments
  6. MOTO UNI $55 1 payment
  7. GMK $31 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Medacta USA, Inc. $84,128 12 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

353

Median for Orthopedic Surgery: 203

Drug cost

$1,717

Median for Orthopedic Surgery: $1,433

Branded share of claims

20.4%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 72 $822
Methylprednisolone Generic 102 $408
Oxycodone Hcl Generic 35 $259
Tramadol Hcl Generic 62 $154
Amoxicillin Generic 44 $44
Clindamycin Hcl Generic 38 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$90,029

Of which drugs: $37

Medicare patients

106

Average age 74

Services billed

413

72 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 19%
Depression 19%
Chronic kidney disease 16%
Atrial fibrillation 14%
Osteoporosis 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 52 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record